Chick, I may have said this before, but the potential of the upcoming pipelines and their broad aplicability to multiple indications in the non-resonder environment with an already predictable amazing safety profile, do to it ability to lower even the toxicity of it's combination drug, make this a multi billion company. $30 a share is "Chick"en-feed :)